All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the ESH Translational Research Conference, the Lymphoma Hub was pleased to speak with Anthony Mato, Memorial Sloan Kettering Cancer Center, New York, US. We asked, How do you decide between continuous or time-limited therapy for CLL?
How do you decide between continuous or time-limited therapy for CLL?
Mato begins by outlining the current continuous treatment approaches, as well as next-generation agents acalabrutinib and zanubrutinib. Mato goes on to discuss venetoclax combinations as time-limited approaches, and the lack of long-term data on venetoclax compared with BTK inhibitors. Finally, Mato discusses how the decision between continuous or long-term approaches should take the individual patient into consideration.
Lymphoma Hub Symposium | The value of BTK inhibitors for the treatment of patients with R/R CLL
A summary of the therapeutic value of BTK inhibitors in the R/R CLL setting and their journey into clinic.
SOHO 2019 | Beyond ibrutinib and venetoclax, what are other novel targeted therapies for CLL treatment?
At SOHO 2019, Dr Jennifer Woyach spoke to us about novel targeted therapies for chronic lymphocytic leukemia (CLL) - small molecule inhibitors...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox